Datapoint: FDA Approves Lilly’s New Alzheimer’s Drug

The FDA on July 2 granted full approval to Eli Lilly’s Kisunla (donanemab) for the treatment of Alzheimer’s disease. The new therapy joins Eisai and Biogen’s Leqembi (lecanemab) in the burgeoning Alzheimer’s market basket. The two drugs’ indications are very similar — they are approved for use in adult patients in the early stages of the disease, experiencing mild cognitive impairment, and also require confirmation of amyloid beta pathology in eligible patients’ brain tissue. But Kisunla may have one major edge over Leqembi — therapy can be stopped once amyloid plaques are removed, “which can result in lower treatment costs and fewer infusions,” Lilly wrote in its press release. Leqembi currently holds covered or better status for 72% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 7/8/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 18

Datapoint: Arcutis Scores New Indication for Zoryve

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 17

Datapoint: Blue Shield of California Adds New Weight Loss, Diabetes Programs to Digital Health Platform

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 16

Datapoint: Sanford, Marshfield Clinic to Merge

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today